Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + RIC for Allo-HSCT in Elderly High-Risk Myeloid Malignancies
NCT05583175Phase 2Unknown
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myelodysplastic/myeloproliferative neoplasm (MDS/MPN). Status: unknown.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT05583175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583175.